We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed the most recent trading day at $11.27, moving -10.31% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.58%. Elsewhere, the Dow gained 0.49%, while the tech-heavy Nasdaq added 0.45%.
Heading into today, shares of the vaccine maker had gained 22.9% over the past month, outpacing the Medical sector's loss of 4.26% and the S&P 500's gain of 0.84%.
The upcoming earnings release of Novavax will be of great interest to investors. The company's upcoming EPS is projected at -$0.37, signifying a 40.32% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $42.96 million, indicating a 39.01% downward movement from the same quarter last year.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of -$0.46 per share and revenue of $357.88 million. These results would represent year-over-year changes of -117.83% and -68.15%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novavax. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Novavax is currently a Zacks Rank #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 179, which puts it in the bottom 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Novavax (NVAX - Free Report) closed the most recent trading day at $11.27, moving -10.31% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.58%. Elsewhere, the Dow gained 0.49%, while the tech-heavy Nasdaq added 0.45%.
Heading into today, shares of the vaccine maker had gained 22.9% over the past month, outpacing the Medical sector's loss of 4.26% and the S&P 500's gain of 0.84%.
The upcoming earnings release of Novavax will be of great interest to investors. The company's upcoming EPS is projected at -$0.37, signifying a 40.32% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $42.96 million, indicating a 39.01% downward movement from the same quarter last year.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of -$0.46 per share and revenue of $357.88 million. These results would represent year-over-year changes of -117.83% and -68.15%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novavax. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Novavax is currently a Zacks Rank #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 179, which puts it in the bottom 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.